ZYME Zymeworks Inc.
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.…
Industry Peers
BiotechnologyKey Statistics
About Zymeworks (NASDAQ: ZYME)
›
Zymeworks (NASDAQ: ZYME) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 279 employees.
The shares were at 26.24 USD on 13 November 2026, up 35.5% over 52 weeks. Its 52-week range is 18.20 USD to 31.96 USD: the price is 17.9% below the high and 44.2% above the low.
At a market capitalisation of 1.85B USD, it trades at 49.5 times trailing earnings and 43.4 times forward earnings. The median trailing P/E of its 14 largest Biotechnology peers is 35.0, a premium of 41% for ZYME.
Zymeworks reports return on equity of -30.2%, an operating margin of 22.6% and revenue up 828.7% year over year.
It holds more cash than debt, a net cash position of 47.34M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 14 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 42.43 USD is 61.7% above the current price. The next earnings report is expected on 4 March 2027.